Trial reportBritish journal of haematology2026
Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.
Trial report in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04962126 (Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Follicular lymphoma (FL) first-line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment-naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)-adapted ultra-low dose radiotherapy (RT; 4Gy) to all PET-avid sites after cycle 2, followed by 2 years of obinutuzumab maintenance. Sixteen eligible patients were enrolled (15 evaluable for response) to our Phase II trial (NCT04962126). Median age was 53 years with 94% intermediate/high Follicular Lymphoma International Prognostic Index (FLIPI) score. The primary end-point of complete response (CR) was achieved in 93% (95% confidence interval [CI]: 70%-99%) with objective response rate (ORR) of 100% (95% CI: 75%-100%). With 41-month median follow-up, 3-year progression-free survival (PFS) was 80% (95% CI: 55-93) and OS was 100% (95% CI: 79.6-100). Grade 3-4 adverse events occurred in 31% of patients (2 immune-related). Baseline PET radiomics and immune transcriptomics demonstrated profiles suggesting promise as predictive markers of immunotherapy response, consistent with our prior findings. The novel multimodality combination of obinutuzumab, atezolizumab and ultra-low dose nodal RT in treatment-naïve FL has promising efficacy and safety, offering a potential novel chemo-free option. Further studies using low-cost RT to augment immunotherapy are warranted. This trial was registered in clinicaltrials.gov, registration number: NCT04962126.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.